Biotech IPO Activity Shows Signs of Momentum
After a prolonged period of limited public market activity, the US biotech sector saw a notable shift last week. Several biotech companies completed IPOs or filed to go public, collectively raising more than $1 billion. Leading industry media have described this as a selective reopening of the IPO market, rather than a broad-based recovery.
Recent IPOs and filings (as reported):
• Eikon Therapeutics raised significant capital to advance next-generation oncology programs
• Veradermics went public to support development of novel treatments for hair loss
• Agomab Therapeutics listed with a focus on immunology and fibrotic diseases
• SpyGlass Pharma completed an IPO to fund long-acting ophthalmology therapies
• Generate Biomedicines filed for an IPO, leveraging an AI-driven drug discovery platform
While these companies span oncology, immunology, fibrosis, ophthalmology, dermatology, and AI-enabled drug discovery, the investment criteria appear consistent. In each case, companies presented clear clinical development plans, credible CMC and manufacturing strategies, and defined use of proceeds beyond listing.
Public markets remain cautious, but capital is flowing to companies that have moved beyond early concepts and can demonstrate visibility into the next phase of development. The latest activity suggests that execution readiness, rather than therapeutic focus alone, is once again shaping investor decisions.
Greenstaff Life Sciences congratulates all teams that completed or filed for IPOs and will continue to follow developments in public markets alongside progress across clinical and development stages.